tiprankstipranks
Unicharm Corporation (JP:8113)
:8113
Want to see JP:8113 full AI Analyst Report?

Unicharm (8113) AI Stock Analysis

8 Followers

Top Page

JP:8113

Unicharm

(8113)

Select Model
Select Model
Select Model
Outperform 77 (OpenAI - 5.2)
Rating:77Outperform
Price Target:
¥1,161.00
▲(21.29% Upside)
Action:Upgraded
Date:08/09/26
The score is primarily supported by strong underlying financial durability (very low leverage and reliable free cash flow) and a constructive technical trend with positive momentum. Offsetting these positives, valuation is less attractive due to a higher P/E and only a modest dividend yield, while recent profitability and growth have softened versus prior peak years.
Positive Factors
Conservative balance sheet
Extremely low leverage (debt ~1% of equity) gives Unicharm durable financial flexibility and downside protection versus peers. This conservative structure supports capital allocation for R&D, capacity additions, or buybacks during cycles, reducing refinancing and solvency risk.
Negative Factors
Uneven and negative revenue trend
Recent negative revenue growth signals softening top-line momentum that may persist absent clear market share gains or geographic expansion. For a volume-driven consumables firm, sustained revenue weakness compresses scale advantages, reduces bargaining power with retailers, and limits reinvestment capacity.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Extremely low leverage (debt ~1% of equity) gives Unicharm durable financial flexibility and downside protection versus peers. This conservative structure supports capital allocation for R&D, capacity additions, or buybacks during cycles, reducing refinancing and solvency risk.
Read all positive factors

Unicharm (8113) vs. iShares MSCI Japan ETF (EWJ)

Unicharm Business Overview & Revenue Model

Company Description
Unicharm Corporation engages in the manufacturing and sale of pet care and related products in Japan and internationally. The company operates through Personal Care, Pet Care, and Others segments. It offers wellness care, feminine care, baby and c...
How the Company Makes Money
Unicharm makes money primarily by manufacturing and selling branded fast-moving consumer goods (FMCG) in hygiene and personal care, supplemented by pet care products. Revenue is generated mainly through product sales to retailers, wholesalers, and...

Unicharm Earnings Call Summary

Earnings Call Date:Aug 05, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 06, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted strong performance in Japan and North America, along with strategic shareholder returns. However, significant challenges in Asia, particularly China, and a downward revision of forecasts indicate a cautious outlook.
Positive Updates
Japan Business Performance
The Japan business achieved a 4.1% increase in net sales and a 2.9% increase in core operating income, marking the highest results ever recorded. This was driven by successful new products and an improved sales mix in wellness and pet care.
Negative Updates
Decline in Core Operating Income
Core operating income decreased by JPY16.1 billion this fiscal year, with a significant decline in Asia, particularly in China, Indonesia, and Thailand.
Read all updates
Q2-2025 Updates
Negative
Japan Business Performance
The Japan business achieved a 4.1% increase in net sales and a 2.9% increase in core operating income, marking the highest results ever recorded. This was driven by successful new products and an improved sales mix in wellness and pet care.
Read all positive updates
Company Guidance
In the second quarter of the fiscal year ending December 31, 2025, Unicharm Corporation reported consolidated sales of JPY464.2 billion, a decline of 4.8%, and a core operating income of JPY57 billion, down 22% compared to the previous year. The decline was attributed to the reaction to record-high profits from the same period last year and reputational incidents affecting feminine care sales in China. Strategic marketing investments in Asia and rising logistics and DX-related costs in Japan also pressured earnings. Interim income attributable to owners increased due to JPY5.3 billion in insurance income from India and the utilization of tax loss carryforwards. In Japan, net sales increased by 4.1% and core operating income by 2.9%, driven by the penetration of the value shift in wellness care and pet care. In contrast, Asia saw a significant decline in net sales by 14.5% and core operating income by 69.4%, primarily due to challenges in China, Indonesia, and Thailand. For the rest of the world, net sales increased by 2.3%, and core operating income rose by 12.7%, with a strong performance in North America's pet care business and the Middle East. The company revised its earnings forecast downward, citing slower-than-expected recovery in Asia, ongoing challenges in China, and demographic shifts affecting the baby care market. Unicharm aims for a total return ratio of 50% or more for shareholders, planning to increase dividends and acquire additional treasury stock.

Unicharm Financial Statement Overview

Summary
High financial quality driven by an extremely conservative balance sheet (debt ~1% of equity) and consistently positive free cash flow with solid cash-to-earnings coverage (~80% TTM). Profitability remains healthy (gross margin ~38%, operating margin ~11%), but revenue has been uneven and net margin has cooled to ~6% TTM versus stronger 2023–2024 levels, limiting the score.
Income Statement
78
Positive
Balance Sheet
92
Very Positive
Cash Flow
84
Very Positive
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue968.23B945.27B988.98B941.79B898.02B782.72B
Gross Profit373.78B355.85B376.38B340.39B318.24B303.11B
EBITDA158.94B157.12B184.32B179.07B160.00B161.41B
Net Income64.43B65.21B81.84B86.05B67.61B72.75B
Balance Sheet
Total Assets1.23T1.22T1.24T1.13T1.05T987.65B
Cash, Cash Equivalents and Short-Term Investments254.47B253.09B353.94B334.38B292.95B293.05B
Total Debt13.32B11.05B61.83B61.34B57.12B75.46B
Total Liabilities324.47B331.92B366.26B345.38B340.61B352.22B
Stockholders Equity811.59B794.71B773.06B695.72B618.88B557.64B
Cash Flow
Free Cash Flow108.71B102.84B97.77B124.00B59.27B70.58B
Operating Cash Flow133.75B131.47B137.10B162.41B92.22B105.25B
Investing Cash Flow-74.49B-55.94B-73.84B-67.45B-4.28B-79.84B
Financing Cash Flow-85.88B-86.64B-66.79B-67.09B-64.52B-45.18B

Unicharm Technical Analysis

Technical Analysis Sentiment
Positive
Last Price957.20
Price Trends
50DMA
949.52
Positive
100DMA
940.59
Positive
200DMA
936.61
Positive
Market Momentum
MACD
16.07
Negative
RSI
60.32
Neutral
STOCH
49.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:8113, the sentiment is Positive. The current price of 957.2 is below the 20-day moving average (MA) of 984.01, above the 50-day MA of 949.52, and above the 200-day MA of 936.61, indicating a bullish trend. The MACD of 16.07 indicates Negative momentum. The RSI at 60.32 is Neutral, neither overbought nor oversold. The STOCH value of 49.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:8113.

Unicharm Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
80
Outperform
¥241.72B28.284.66%5.68%-2.85%
77
Outperform
¥1.84T29.167.73%2.09%-2.89%-31.75%
74
Outperform
¥2.96T23.4612.16%2.36%3.60%13.80%
72
Outperform
¥554.51B15.7612.11%1.82%11.37%11.35%
64
Neutral
¥463.55B17.028.90%1.74%3.10%27.99%
62
Neutral
$20.33B14.63-3.31%3.23%1.93%-12.26%
58
Neutral
¥1.26T-35.011.64%0.45%-836.50%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:8113
Unicharm
1,023.00
35.17
3.56%
JP:4452
Kao
3,654.00
292.85
8.71%
JP:4912
Lion
1,797.50
202.86
12.72%
JP:4527
Rohto Pharmaceutical Co
2,862.50
406.71
16.56%
JP:4911
Shiseido Company,Limited
3,619.00
1,104.95
43.95%
JP:7956
Pigeon Corporation
2,092.50
443.77
26.92%

Unicharm Corporate Events

Unicharm Releases Q2 FY2026 Investor Presentation Materials
Aug 5, 2026
Unicharm has released presentation materials for its investor meeting covering the second quarter of the fiscal year ending December 31, 2026, spanning results from January 1 to June 30. The documents are positioned as a financial performance summ...
Unicharm Delivers Higher Sales and Strong Core Earnings, Lifts Dividend and Full-Year Guidance
Aug 5, 2026
Unicharm reported consolidated net sales of ¥487.1 billion for the six months ended June 30, 2026, a 4.9% year-on-year increase, with core operating income rising 14.1% to ¥65.0 billion. Profit attributable to owners of the parent slippe...
Unicharm Discloses Parent Unitec’s FY2026 Results and Ownership Structure
Jun 15, 2026
Unicharm has announced that its parent entity, Unitec Corporation, has finalized financial statements for the fiscal year ended March 20, 2026, fulfilling disclosure obligations for a parent company that holds a significant voting stake. Unitec is...
Unicharm Moves to Enter Brazil’s Pet Food Market With Nutrire Acquisition
May 15, 2026
Unicharm’s consolidated subsidiary, UNICHARM PET DO BRASIL LTDA, has agreed to acquire all shares of Brazilian pet food maker Nutrire Indústria de Alimentos, which produces and sells premium pet food domestically and exports mainly to C...
Unicharm Boosts Capital in Brazilian Pet Unit for Full-Scale Market Entry
May 15, 2026
Unicharm Corporation will significantly increase the capital of its Brazilian pet subsidiary, UNICHARM PET DO BRASIL LTDA, as it makes a full-scale entry into Brazil’s pet market, which the company positions as a key growth area. The capital...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 09, 2026